Want to see PHVS full AI Analyst Report?
Top Page
Pharvaris
(NASDAQ:PHVS)
Select Model
Select Model
Rating:58Neutral
Price Target:
$35.00
▼(-5.99% Downside)
Action:Reiterated
Date:09/09/26
Overall score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), partially offset by a strong low-debt balance sheet. Technical conditions are currently favorable with the price in an uptrend and positive momentum, but valuation remains challenging due to negative earnings and no dividend.
Positive Factors
Phase 3 efficacy and regulatory progress
Strong Phase 3 prophylaxis results, combined with active FDA and EMA review, materially improve the credibility of deucrictibant as a future commercial product. The oral formulation and consistent efficacy support differentiation in HAE and create a clearer path toward potential launches.
Negative Factors
Pre-revenue business model
Pharvaris has not yet generated product revenue, so its operating model remains dependent on successful clinical development, regulatory approvals, and eventual commercialization. Until those milestones occur, there is no established revenue base to offset development costs or validate recurring demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 efficacy and regulatory progress
Strong Phase 3 prophylaxis results, combined with active FDA and EMA review, materially improve the credibility of deucrictibant as a future commercial product. The oral formulation and consistent efficacy support differentiation in HAE and create a clearer path toward potential launches.
Read all positive factors
Pharvaris (PHVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.34B
Dividend YieldN/A
Average Volume (3M)646.83K
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue GrowthN/A
EPS Growth9.42%
CountryUS
Employees148
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.70
Shares Outstanding69,863,686
10 Day Avg. Volume645,254
30 Day Avg. Volume646,826
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.70K
Enterprise Value/Ebitda-11.56
Forecast
1Y Price Target
$61.33Price Target Upside64.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.8
Revenue Forecast (FY)N/A
Pharvaris Business Overview & Revenue Model
Company Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant...
Pharvaris Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -106.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -172.17M | -173.29M | -145.42M | -99.57M | -86.56M | -42.31M |
| Net Income | -171.57M | -175.70M | -134.22M | -100.88M | -76.33M | -42.73M |
Balance Sheet | ||||||
| Total Assets | 328.67M | 301.45M | 291.37M | 398.69M | 167.73M | 212.09M |
| Cash, Cash Equivalents and Short-Term Investments | 318.28M | 291.68M | 280.73M | 391.23M | 161.84M | 209.35M |
| Total Debt | 673.73K | 776.80K | 861.47K | 238.91K | 436.82K | 250.18K |
| Total Liabilities | 27.86M | 30.18M | 23.61M | 14.65M | 18.47M | 7.14M |
| Stockholders Equity | 300.81M | 271.27M | 267.76M | 384.05M | 149.26M | 204.95M |
Cash Flow | ||||||
| Free Cash Flow | -156.09M | -137.24M | -120.67M | -93.14M | -67.29M | -44.73M |
| Operating Cash Flow | -155.99M | -137.07M | -120.13M | -93.05M | -67.16M | -44.60M |
| Investing Cash Flow | -100.11K | -164.62K | -538.09K | -89.98K | -124.30K | -130.03K |
| Financing Cash Flow | 266.52M | 160.61M | 2.68M | 325.39M | 8.65M | 143.67M |
Pharvaris Technical Analysis
Positive
37.23
Price Trends
33.66
Negative
33.83
Negative
31.00
Positive
Market Momentum
-0.10
Negative
59.57
Neutral
96.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Positive. The current price of 37.23 is above the 20-day moving average (MA) of 31.03, above the 50-day MA of 33.66, and above the 200-day MA of 31.00, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 59.57 is Neutral, neither overbought nor oversold. The STOCH value of 96.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHVS.
Pharvaris Risk Analysis
Pharvaris disclosed 82 risk factors in its most recent earnings report. Pharvaris reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our articles of association designate specific courts as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. Q4, 2023
2.
to successfully commercialize our product candidates, or experience significant delays in doing so, our business, financial condition, results of operations and prospects would be materially adversely affected. Q4, 2023
Pharvaris Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $864.10M | 34.56 | 8.96% | ― | 6.67% | 2242.07% | |
59 Neutral | $1.33B | 9.65 | -109.40% | ― | ― | ― | |
58 Neutral | $2.34B | -11.10 | -61.24% | ― | ― | 9.42% | |
58 Neutral | $2.16B | -5.89 | 101.55% | ― | 68.72% | -737.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.37B | -2.50 | -87.96% | ― | -12.60% | -126.24% |
* Healthcare Sector Average
PHVS
Pharvaris
33.53
11.03
49.02%
BCRX
BioCryst
8.47
1.61
23.47%
OMER
Omeros
18.44
11.27
157.18%
KRSA
Korsana Biosciences
30.14
17.12
131.49%
PHAR
Pharming Group
12.23
-1.09
-8.18%
ADRX
ADARx Pharmaceuticals
17.00
-2.35
-12.14%
Pharvaris Corporate Events
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones
Sep 8, 2026
Pharvaris N.V., based in Leiden, the Netherlands, is a clinical‑stage biopharmaceutical company focused on hereditary angioedema (HAE). Its lead investigational products, deucrictibant immediate‑release capsules for on‑demand tre...
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR
Sep 8, 2026
On September 8, 2026, Pharvaris reported positive topline results from its CHAPTER-3 pivotal Phase 3 study of once-daily deucrictibant XR for prophylaxis of hereditary angioedema attacks. The global, double-blind trial in 85 adolescents and adults...
Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones
Aug 12, 2026
On August 12, 2026, Pharvaris reported second-quarter 2026 results and highlighted continued clinical and regulatory momentum for deucrictibant, including an FDA review of the immediate-release capsule for on-demand hereditary angioedema treatment...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.